Idorsia | Portfolio overview

Search

Search
Share
Share
Facebook

Twitter

LinkedIn

Mail
Location

Location
Contact
Contact
General Contact

General Contact:

Idorsia Pharmaceuticals Ltd
Hegenheimermattweg 91
4123 Allschwil
Switzerland

+41 58 844 00 00

Please get in touch with us via the contact form by clicking "Next".

For patients and healthcare professionals

Investor Relations

Media Relations

Business Development

Whistleblower hotline

Whistleblower hotline:

Switzerland: 0800 110 007

USA: (833) 222-3891 (anonymous reporting channel)

Outside Switzerland and USA: +41 58 844 0106

Learn more about our Governance by clicking "Next"

Data Protection Officer

Data Protection Officer:

Idorsia attempts to ensure that your Personal Data are updated, accurate, and complete according to the information that has been provided. Any request related to the exercise of your privacy rights can be sent through the link below.

Webmaster

Stay informed

Stay informed:

To best serve your interest, Idorsia offers an electronic ‘Stay Informed’ service. With this service you have the possibility to automatically receive Idorsia's Media Releases directly to your inbox. In addition, if you provide your mobile phone number, we will send you an alert via SMS when the media release is published.

Bench to bedside

Bench to bedside

Learn all about our strategic priorities to enable delivery on our ambitious goals.
Portfolio
Portfolio

Idorsia aims to deliver new products with the potential to significantly change the treatment options in their target diseases. We want to bring new perspectives to the discovery, development, and commercialization of innovative treatments, challenging accepted paradigms to answer the questions that matter most.
Target Diseases
Target Diseases

Our drug discovery approach has led to a pipeline of compounds that are active in many different therapeutic areas. Learn more about the diseases that we are targeting.
Serving patients

Serving patients

Idorsia-led Portfolio

Compound	Mechanism of action	Target indication	Status	More Information

QUVIVIQ™ (daridorexant)	Dual orexin receptor antagonist	Insomnia	Commercially available in the US, Germany, Italy, Switzerland, Spain, the UK, Canada, Austria, and France; approved throughout the EU	Investor webcast
TRYVIO™ (aprocitentan)	Dual endothelin receptor antagonist	Systemic hypertension in combination with other antihypertensive drugs	Approved in the US, product availability planned for Q4 2024	Investor webcast
JERAYGO™ (aprocitentan)	Dual endothelin receptor antagonist	Resistant hypertension in combination with other antihypertensive drugs	Approved in the EU. Marketing authorization applications for the UK, Canada, and Switzerland in preparation	Investor webcast
Lucerastat	Glucosylceramide synthase inhibitor	Fabry disease	Phase 3 primary endpoint not met, open-label extension study ongoing Phase 3 focused on renal function in preparation
ACT-1004-1239	ACKR3/CXCR7 antagonist	Demyelinating diseases including multiple sclerosis	Phase 2 in preparation
ACT-777991	CXCR3 antagonist	Vitiligo	Phase 2 in preparation
Sinbaglustat	GBA2/GCS inhibitor	Rare lysosomal storage disorders	Phase 1 complete
IDOR-1117-2520	Undisclosed	Immune-mediated disorders	Phase 1 ongoing
IDOR-1134-2831	Synthetic glycan vaccine	Clostridium difficile infection	Phase 1 ongoing

Partner-led Portfolio

Compound	Mechanism of action	Target indication	Partner: Terms	Status
QUVIVIQ™ (daridorexant)	Dual orexin receptor antagonist	Insomnia	Simcere: license to develop and commercialize for the Greater China region	Approved for the treatment of insomnia in Hong-Kong
Daridorexant	Dual orexin receptor antagonist	Insomnia	*Nxera Pharma:** license to develop and commercialize for Asia-Pacific region (excluding China)	NDA submitted in Japan
Daridorexant	Dual orexin receptor antagonist	Insomnia	Simcere: license to develop and commercialize for the Greater China region	NDA submitted in Greater China
Selatogrel	P2Y₁₂ inhibitor	Suspected acute myocardial infarction	Viatris: worldwide development and commercialization rights	Phase 3 “SOS-AMI” program ongoing
Cenerimod	S1P₁ receptor modulator	Systemic lupus erythematosus	Viatris: worldwide development and commercialization rights (excluding Japan, South Korea, and certain countries in the Asia-Pacific region)	Phase 3 “OPUS” program ongoing
Daridorexant	Dual orexin receptor antagonist	Posttraumatic stress disorder (PTSD)	US Department of Defense (DOD): Idorsia supports a clinical study sponsored by the US DOD to develop new therapies to treat PTSD	Phase 2
ACT-709478/ NBI-827104	T-type calcium channel blocker	Epileptic encephalopathy with continuous spike-and-wave during sleep (CSCW)	Neurocrine Biosciences: global license to develop and commercialize	Phase 2 OLE study ongoing
ACT-1002-4391	EP₂ / EP₄ receptor antagonist	Immuno-oncology	Owkin: global license to develop and commercialize	Phase 1 in preparation

* In Japan, Idorsia has a license agreement with Mochida Pharmaceutical for the supply, co-development and co-marketing of daridorexant. All potential milestones have been assigned to Nxera